The round was led by IP Group Australia and super fund Hostplus, with support from existing investors including Monash Ventures. The funds will go towards first-in-human clinical trials for Rage’s nasal therapy to treat inflammatory lung diseases
The startup’s name is an acronym of Receptor for Advanced Glycation End-products (RAGE), a receptor involved in inflammation in chronic lung diseases and other conditions.
Rage Bio was founded as a spinout between IP Group Australia and Monash, Murdoch and WA universities and the and the Baker and Perron medical research institutes, to develop technology and treatments for inflammatory disorders.
Full story: University biotech spinout Rage lands $29 million Series A – Startup Daily
